ERBB2 and breast carcinoma: HER2-positive breast cancer has a high frequency of TP53 mutations (up to 72%) [8], and in our previous study, the mutation frequency of TP53 in the triple-positive HR + /HER2 + group is 66.1% and up to 89.3% in the HR-/HER2 + group in Chinese breast cancer patients [19].